Tests retatrutide and tirzepatide in adults with fatty liver disease at high risk
Tests retatrutide and tirzepatide in adults with fatty liver disease to prevent serious liver problems.
Plain-language title generated from the registry record
Registry title: A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Key facts
- Where
- ABB, Buenos Aires, Córdoba, Granadero Baigorria, Mar del Plata, Ramos Mejía, Rosario, and Santa Fe, ArgentinaSee the 17 sites
- Phase
- Phase 3
Where in Argentina
- Hospital Italiano de Buenos AiresABB, ArgentinaTaking people
- Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaTaking people
- Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaTaking people
- Centro Médico ViamonteBuenos Aires, ArgentinaTaking people
- Cicemo SrlBuenos Aires, ArgentinaTaking people
- CIPRECBuenos Aires, ArgentinaTaking people
- DOM Centro de ReumatologíaBuenos Aires, ArgentinaTaking people
- Fundacion RespirarBuenos Aires, ArgentinaTaking people
- Glenny Corp. S.A.Buenos Aires, ArgentinaTaking people
- Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaTaking people
- Instituto de Investigaciones Clínicas CórdobaCórdoba, ArgentinaTaking people
- Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaTaking people
- Instituto de Investigaciones Clinicas Mar del PlataMar del Plata, ArgentinaTaking people
- DIM Clínica PrivadaRamos Mejía, ArgentinaTaking people
- INECO Neurociencias OroñoRosario, ArgentinaTaking people
- Instituto de Investigaciones Clinicas RosarioRosario, ArgentinaTaking people
- Centro de Diagnóstico y Rehabilitación (CEDIR)Santa Fe, ArgentinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07165028EU 2025-522674-36-00
- Record updated
- 8 October 2026
- Original description
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression.Read full original descriptionShow less
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO. Participants will be randomly assigned within a Master Protocol to receive either retatrutide (N1T-MC-RT01), tirzepatide (N1T-MC-TZ01) or placebo. The trial plans to enroll about 4,500 adults and will run for approximately 224 weeks. Participants may have up to approximately 25 to 30 clinic visits throughout the study to monitor their health, complete study procedures, and assess liver function and disease progression.
Once the study is complete, eligible participants may participate in an optional 2-year extension study, in which all participants will receive either retatrutide or tirzepatide, even if they received placebo in the main study.
Inclusion: Have liver fat content ≥8%; Have ELF score of ≥9 and ≤10.8 at screening; Have VCTE LSM ≥10 kilopascal (kPa) and <20 kPa at screening.
Exclusion: Prior decompensated liver disease (history of esophageal/gastric varices, ascites, hepatic encephalopathy); Have lost more than 11 pounds within the 3 months prior to screening; Have any other type of liver disease other than MASLD; Have type 1 diabetes; Have a hemoglobin A1c (HbA1c) greater than 10%; Have a body mass index (BMI) <25 kilogram per square meter (kg/m2).